Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline
This article was originally published in The Gray Sheet
Executive Summary
Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments